Clinical Trials | Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System among Adolescents with T1D [Launchpad Lyumjev]

The Center for Diabetes Technology seeks people ages 12-22 with type 1 diabetes who are currently using a Tandem Control-IQ insulin pump for a research study. The purpose of this study is to test whether use of Lyumjev insulin results in better blood sugars compared to Humalog or Novolog. This will be evaluated specifically in the Tandem Control-IQ system, using doses determined by our dose conversion factor. You may be eligible for this study if: you are between the ages of 12 and 22, have been diagnosed with type 1 diabetes for at least 1 year, and are currently using a Tandem Control-IQ insulin pump. The study involves 10 visits over about 9 weeks. The study can be completed entirely remotely, but you may need to be seen in-person at UVA or go to a local lab to have your A1c measured. Lyumjev insulin and study-related tests will be provided at no cost. Study participants will use their own Novolog or Humalog insulin, Tandem Control-IQ pump, and Dexcom sensors. Participants will be eligible to receive $200 for completing all study procedures. For more information, please scan the QR code below or contact the study coordinator, Sara Prince at [email protected] or 434-320-5599.